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OBJECTIVES The goal of this study was to determine how often atrioventricular (AV) block is really caused
by medications.
BACKGROUND Beta-blockers, verapamil, and diltiazem are considered a cause of AV block for which
pacemaker implantation is not indicated. However, it is not known if such patients can expect
a benign course after discontinuation of the culprit medication.
METHODS Consecutive patients with II or III degree AV block not related to acute myocardial
infarction, digitalis toxicity, or vasovagal syncope were studied. The level of AV block
(AV-nodal or infranodal) was defined by electrocardiographic criteria. The cause and effect
relation between AV block and drugs was defined according to the response to drug
discontinuation.
RESULTS Of 169 patients with AV block, 92 (54%) were receiving beta-blockers and/or verapamil or
diltiazem. Patients receiving medications had similar clinical and electrocardiographic
characteristics with patients who had AV block in the absence of drugs. Drug discontinuation
was followed by resolution of AV block in 41% of cases, whereas spontaneous improvement
of AV conduction occurred in 23% of patients who had AV block in the absence of drugs.
However, 56% of the patients for whom drug discontinuation led to resolution of AV block
had recurrence of AV block in the absence of therapy. Atrioventricular block that was “truly
caused by drugs” was found in only 15% of patients who had II or III degree AV block during
therapy with beta-blockers, verapamil, or diltiazem.
CONCLUSIONS Atrioventricular block is commonly “related to drugs” but is rarely “caused by drugs.” (J Am
Coll Cardiol 2004;44:105–8) © 2004 by the American College of Cardiology FoundationM
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reta-blockers and nondihydropyridine calcium channels
ntagonists (verapamil and diltiazem) are considered a
ommon cause of acquired complete atrioventricular (AV)
lock in clinical practice. This is often stated axiomatically
n reviews of the topic in major journals (1,2) and in
extbooks of cardiology (3–5). However, it is unclear if AV
lock discovered in patients treated with beta-blockers or
alcium channel blockers merely unmasks the presence of
erious underlying AV conduction disease. More impor-
antly, little is known about the natural history and prog-
osis of patients with drug-related AV block. In other
ords, it is not known if patients with “drug-induced AV
lock” can expect a benign course after discontinuation of
he offending medication. This is of clinical importance
ecause, according to contemporaneous guidelines (6),
acemaker implantation is generally considered unnecessary
n patients with drug-induced AV block. We, therefore,
xamined the clinical course of consecutive patients admit-
ed to our institution with the diagnosis of “AV block” and
ompared the clinical characteristics and evolution of pa-
ients who had AV block while receiving beta-blockers,
iltiazem, or verapamil to those of patients who had AV
lock in the absence of drugs.
From the Departments of *Internal Medicine D and †Cardiology, Tel Aviv–
ourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel
viv, Israel. Drs. Zeltzer and Justo contributed equally to this work.
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e reviewed all cases admitted or discharged from our
nstitution between October 1999 and July 2003 with a
iagnosis of “AV block.” In addition, beginning in April
002, we prospectively collected data from all patients
dmitted to our institution, for whom consultation for “AV
lock” was requested from our cardiac arrhythmia service.
atients were included in this study if they had second-
egree or third-degree AV block. Patients were excluded if
heir AV block was attributed to acute myocardial infarc-
ion, vasovagal syncope, digitalis toxicity, or radiofrequency
blation. We also excluded patients treated with class I and
lass III antiarrhythmic drugs. Collection and analysis of
ata was authorized by the ethics committee of the hospital.
The estimated level of AV block was characterized
ccording to electrocardiographic characteristics (Table 1)
7–11). Also, to define the cause and effect relation between
eta-blockers or calcium channel blocker therapy and AV
lock, patients were classified into the following groups: 1)
V block in the absence of drugs: AV block occurred in the
bsence of drugs that affect AV conduction; 2) drug-related
trioventricular block (DR-AVB): AV block diagnosed
uring therapy with verapamil, diltiazem, or beta-blockers.
atients in the last group were further classified as follows:
A) DR-AVB caused by drugs: drug-related AV block that
esolved when the drugs were discontinued and never
ecurred during a follow-up period (3 weeks); 2B) DR-
VB not caused by drugs: drug-related AV block that
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Drug-Induced Atrioventricular Block July 7, 2004:105–8esolved spontaneously despite ongoing therapy with the
ame medications or resolved within 48 h after drug discon-
inuation but then recurred (within three weeks) in the
bsence of therapy. 2C) DR-AVB undetermined relation:
V block occurred during drug therapy, but the cause and
ffect relation could not be determined because permanent
acemaker implantation was performed, and the medica-
ions were not discontinued.
tatistical analysis. Categorical data were compared using
he chi-square test or Fisher exact test. Continuous variables
ormally distributed were compared by t test. Continuous
ariables without a normal distribution were analyzed by the
ann-Whitney U test. For all analyses, a two-sided p 
.05 was considered statistically significant. Statistical anal-
sis was performed using SPSS version 9 for Windows
SPSS Inc., Chicago, Illinois).
ESULTS
e identified 169 consecutive patients with second- or
hird-degree AV block without exclusion criteria. Of these
atients, 92 (54%) patients were receiving medications
nown to impair AV conduction: 30 patients were receiving
erapamil or diltiazem (177  85 mg/day or 113  73
g/day, respectively), 62 patients were receiving beta-
lockers (metoprolol 100 mg/day, atenolol 52 12 mg/day,
ropranolol 23  8 mg/day, carvedilol 17  13 mg/day, or
isoprolol 3.4  2 mg/day). Thirteen of these patients
14%) were receiving verapamil or diltiazem in addition to a
eta-blocker at the time of the AV block. During the same
ime period, we also identified 77 patients who presented
ith AV block in the absence of drug therapy (Table 2).
Patients with DR-AVB were similar to those with AV
lock occurring in the absence of drugs in terms of clinical
haracteristics (age, gender, and symptoms during AV
lock). Patients with DR-AVB more commonly had hyper-
ension (probably reflecting the original indication for these
edications) and less commonly had organic heart disease
Table 2). Moreover, both patient groups had similar
lectrocardiographic characteristics, including the degree of
Abbreviations and Acronyms
AV  atrioventricular
DR-AVB  drug-related atrioventricular block
able 1. Classification of Second- and Third-Degree AV Block B
AV-Nodal Block
econd-degree AV block PR increment preceding a blocked P
(Wenckebach) and narrow QRS (8)
C
:1 AV block Conducted impulse has long PR and
narrow QRS; PR varies inversely
with RP (11)
C
hird-degree AV block Escape rhythm has narrow QRS and
rate 40 beats/min (7)
EV  atrioventricular.V block as well as the sinus rate, the ventricular escape
ate, and QRS width during AV block. Only a minority of
atients in both groups had electrocardiographic pattern
uggesting AV block at the level of the AV node (16% vs.
% for patients with and without medications, p  NS),
hereas most patients in both groups had infranodal block
Table 2).
Upon hospitalization with AV block, the culprit medica-
ion was discontinued in 79 (86%) of the 92 patients with
R-AVB. Drug discontinuation was followed by sponta-
eous resolution of AV block within 48 h in 32 (41%) of
hese patients. For comparison, spontaneous resolution of
V block within 48 h of admission occurred in only 18
23%) of patients admitted with AV block in the absence of
rugs. In other words, resolution of AV block was, indeed,
ore common after discontinuation of the culprit drug than
n the absence of therapy (32 of 79 [41%] vs. 18 of 77 [23%],
 0.014). However, 18 (56%) of the 32 patients with
R-AVB who had spontaneous resolution of AV block
fter discontinuation of beta-blockers and/or calcium chan-
el blockers developed AV block again (within the follow-
ng three weeks) in the absence of drug therapy. Moreover,
n 10 of these 18 patients, AV block was of worse degree
nd led to syncope. Finally, spontaneous relapse of AV
lock was just as common among patients who originally
ad AV block in the absence of therapy (7 of 18 [38%], p
.16). Six (6%) patients with DR-AVB were receiving
igoxin in addition to beta-blockers or calcium channel
lockers. None of them had clinical or laboratory evidence
f digitalis toxicity. The digitalis was discontinued concom-
tantly with the beta-blockers and calcium channel blockers.
et the AV block persisted despite drug discontinuation in
our of them. One patient in the “drug-free” group was
eceiving digoxin (without evidence for toxicity) at the time
f AV block. The block persisted despite digitalis discon-
inuation.
The presence of electrocardiographic characteristics sug-
esting AV block at the level of the AV node during drug
herapy was a poor predictor of “causation”: 15 patients had
V “nodal” block while receiving beta-blockers or calcium
hannel blockers; in nine (60%) of them, the AV block
ither persisted after drug discontinuation or returned
hortly thereafter.
The following estimates can be made for our patient
opulation (Fig. 1): 1) drug-related AV block is common:
on Electrocardiographic Characteristics
nfra-Nodal AV Block Undetermined Level of AV Block
nt PR interval preceding
ked P (10)
PR increment (Wenckebach) preceding
a blocked P and wide QRS (9)
cted impulse has normal PR
wide QRS; PR is constant
ite varying RP (11)
Conducted impulse has long PR and
wide QRS or short PR and narrow
QRS
rhythm has wide QRS and
40 beats/min (7)
Escape rhythm has wide QRS and rate
40 beats/minased
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July 7, 2004:105–8 Drug-Induced Atrioventricular Block4% of patients hospitalized with second- or third-degree
V block not related to acute myocardial infarction, vaso-
agal syncope, digitalis toxicity, or radiofrequency ablation
eceived medications that are commonly blamed for this
ccurrence; 2) however, DR-AVB that is truly “caused by
he drugs” is rare: according to our prospectively defined
riteria for causation, only 8% of all cases presenting with
V block and only 15% of patients presenting with AV
lock while receiving medications had AV blocked that was
caused by the medications”; 3) the majority of patients
resenting with second- or third-degree AV block during
herapy with beta-blockers or calcium channel blockers will
ontinue to suffer from AV block even after discontinuation
f these medications. Moreover, even when the AV resolves
Table 2. Characteristics of Patients With Seco
AV Block During Drug Thera
(92 Patients)
Age (yrs) 78  9 (range, 54–99)
Males 61 (66%)
Presentation Syncope, 10 (11%)
Pre-syncope, 12 (13%)
Effort intolerance, 62 (67%)
No symptoms, 8 (9%)
Heart disease Ischemic heart disease, 39 (44%
Hypertension, 63 (72%)
Other heart diseases, 9 (10%)
No heart disease, 8 (9%)
Intervals Sinus rate  79  17 (37–111)
PR‡  250  108 (120–600) m
QRS  121  27 (80–180) ms
Longest R-R  1,477  349 m
AV block degree Second-degree 72 (78%)
Third-degree 20 (22%)
AV block level§ AV nodal block 15 (16%)
Infranodal block 52 (56%)
Undetermined 25 (28%)
*Patients with atrioventricular (AV) block caused by vasova
radiofrequency ablation were not included; †Drugs studied i
in ms for patients with second-degree AV block (including th
were not generally recorded, and the level of AV block was
igure 1. Flow chart describing the course of 163 consecutive patients with
trioventricular (AV) block not related to acute myocardial infarction,
asovagal syncope, digitalis toxicity, or radiofrequency ablation. Theuumber of patients in each step appears in parentheses.hen the medications are discontinued, it is likely to recur
n the absence of drug therapy (Fig. 1).
ISCUSSION
e present data on 169 consecutive patients presenting
ith second- or third-degree AV block not related to acute
yocardial infarction, vasovagal syncope, digitalis toxicity,
r radiofrequency ablation. Our patient population con-
isted mainly of elderly patients with structural heart dis-
ase. For these patients, our data suggest that AV block is
ommonly associated with therapy with verapamil, diltiazem,
nd/or beta-blockers but, contrary to common dictum, it is
arely caused by it.
nterpretation of main findings. Roughly one-half of our
atients with AV block were receiving verapamil, diltiazem,
nd/or beta-blockers at the time of presentation. These
edications were almost invariably discontinued soon after
dmission. This policy of drug discontinuation probably
eflects the physicians’ belief that drug therapy represents a
reversible” or “curable” cause of AV block. The fact that
V block often resolves shortly after drug discontinuation
in 41% of cases) is likely to reinforce the impression that
V block is “caused” by drugs. On the other hand, the 23%
ncidence of spontaneous resolution of AV block observed
n patients who never received medications suggests that
mprovement in AV conduction upon cessation of medica-
ions is often coincidental. Moreover, disappearance of AV
lock upon drug discontinuation is likely to be transient.
he 56% (18 of 32) incidence of “AV block relapse”
recurrence of AV block after its apparent resolution fol-
owing drug discontinuation [Fig. 1]) is likely to be an
r Third-Degree AV Block*
AV Block in the Absence of Drugs
(77 Patients) p Value
78  8.5 (range 55–95) 0.78
41 (53%) 0.11
Syncope, 9 (12%) 0.84
Presyncope, 9 (12%)
Effort intolerance, 49 (63%)
No symptoms, 10 (13%)
Ischemic heart disease, 24 (32%) 0.15
Hypertension, 35 (43%) 0.02
Other heart diseases, 6 (8%) 0.39
No heart disease, 28 (38%) 0.001
Sinus rate  85  19 (38–167)/min 0.066
PR‡  232  113 (110–680) ms 0.143
QRS  127  26 (80–190) ms 0.16
Longest R-R  1,515  265 ms 0.45
Second-degree, 61 (80%) 0.99
Third-degree, 16 (20%)
AV nodal block, 6 (8%) 0.1
Infranodal block, 55 (71%)
Undetermined, 16 (20%)
ncope, acute myocardial infarction, or digitalis toxicity, or
d verapamil, diltiazem, and oral beta-blockers; ‡PR interval
est PR interval during type I block); §His-bundle recordings
ted from the electrocardiogram (Table 1).nd- o
py†
)
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e longnderestimation because additional cases of AV block recur-
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Drug-Induced Atrioventricular Block July 7, 2004:105–8ence could have been detected with longer follow-up
eriods.
Our findings, although contradictory of “the common
ictum,” are actually not surprising. Because we excluded
atients with AV block related to acute myocardial infarc-
ion, vasovagal syncope, or digitalis toxicity, our series
overed mainly elderly patients with infranodal conduction
isease. Yet, verapamil, diltiazem, and all beta-blockers
xert their negative dromotropic effects mainly at the level of
he AV node. The limited number of patients in our series
recludes subgroup analysis according to medications’ dos-
ge. Thus, we cannot exclude the possibility that AV block
ccurring in a patient receiving larger doses is more likely to
esolve permanently when the medication is stopped. How-
ver, because of their depressant effects on the sinus rate and
onduction time at the more proximal (AV nodal) seg-
ents, these drugs would be expected to prevent—rather
han provoke—conduction block at the more distal (infra-
odal) segments. One could, therefore, argue that when II
r III degree AV block occurs despite beta-blocker or
alcium channel blockers, the infranodal conduction disease
s more likely to be severe and (sooner or later) become
ermanent.
tudy limitations. We studied elderly patients who were
ospitalized. Our observations cannot be generalized to
mbulatory or younger patients or to those receiving other
edications (particularly digitalis and antiarrhythmic
gents). Also, because His-bundle recording was hardly ever
erformed in our series, the site of block cannot be accu-
ately defined. However, the electrocardiographic character-
stics recorded are fairly accurate in defining infranodal
lock, especially in the elderly patients included in this and
ther series of patients with AV block. Moreover, electro-
ardiographic characteristics were not useful for predicting
bsence of AV block in the absence of drugs.
linical implications. In contemporaneous guidelines,
AV block that is likely to resolve and unlikely to recur, like
hat caused by drug toxicity” is considered a condition for
hich there is “evidence and/or general agreement that
acemaker implantation is not indicated” (6). Accordingly,
atients presenting with AV block while receiving vera-
amil, diltiazem, or beta-blockers are usually monitoredhile the medications are discontinued. Our study suggests
hat, for the majority of patients presenting with AV block,
iscontinuation of medications will not obviate the need for
acemaker implantation. The must likely scenario for pa-
ients who have AV block during drug therapy is that AV
lock will persist after drug discontinuation. A more wor-
isome scenario, however, is the disappearance of AV block
hen drugs are discontinued. Such patients could be dis-
harged without pacemakers according to prevailing guide-
ines (6). Yet, according to our study, these patients are at
reat risk for recurrence of AV block even in the absence of
rugs.
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ent of Cardiology, Tel Aviv Medical Center, Weizman 6, Tel Aviv
4239, Israel. E-mail: saviskin@tasmc.health.gov.il.
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